HUMA
Humacyte IncHenter pris…
Værdiansættelse (TTM)
Kursudvikling
Kun 93 handelsdage i databasen. Viser al tilgængelig historik.
Data-readiness
10 års prishistorik er idealet for høj confidence.
- Prishistorik
- 0,3 år
- Pris-dage
- 74
- Årsregnskaber
- 7
- Peers
- 0/0
- Valuation
- 4/6
- Fundamentals
- 7/8
- Datovindue
- 2026-02-17 til 2026-06-02
Blokkere
- Raw confidence is below the 0.95 high-confidence guardrail.
Mangler før højere confidence
- Mangler ca. 9,7 års prishistorik før ideal/full.
- Backfill mindst 1 års daglige priser før seriøs teknisk vurdering.
- Kør compute-multiples for manglende valuation metrics.
- Kør fetch-fundamentals-bulk/API fallback for manglende regnskabsmetrics.
Seneste assessment
HUMA vurderet 2026-06-10
Raw confidence is below the 0.95 high-confidence guardrail.
Stores exit-aware fields without issuing sell scores yet.
Current drawdown: Future exit logic can use drawdown from recent high.
Trend break: Future exit logic can use moving-average trend breaks.
Compares price paid with earnings, cash-generation proxies and sales.
P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.
Earnings yield: Earnings yield is the inverse P/E lens.
Checks trend, momentum and current damage from recent highs.
6M momentum: Positive medium-term momentum confirms sponsorship.
Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.
Checks whether the assessment has enough recent price, fundamental and valuation data.
Price history depth: More than one trading year gives the technical pillar enough context.
Latest price freshness: Latest live or EOD price should be recent.
Treats macro as context, not a standalone trading instruction.
VIX: Normal volatility is supportive; panic or complacency is less clean.
10Y-2Y curve: Positive yield curve lowers recession stress.
Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.
Revenue growth 3Y: Sustained top-line growth supports durable compounding.
Gross margin: High gross margin gives room for reinvestment and downturns.
Adds relative context when sector peers have comparable data.
Peer count: Peer context is only scored when comparable data exists.
P/E vs peers: Own P/E 15.4 vs peer median 12.6; broadly in line with the peer set.
Insider activity
| Dato | Person | Rolle | Type | Antal | Værdi | Kilde |
|---|---|---|---|---|---|---|
| 20.8.2026 | Jones Keith Anthony | — | ▲ KØB | 10.000 | 6.930 USD | sec |
| 17.8.2026 | Jones Keith Anthony | — | ▲ KØB | 30.000 | 17.820 USD | sec |
| 19.5.2026 | Sebelius Kathleen | — | ▲ KØB | 56.818 | 50.000 USD | sec |
| 18.5.2026 | Constantino Michael T. | — | ▲ KØB | 11.000 | 9.840 USD | sec |
| 18.5.2026 | Sander Dale A. | CFO and Chief Corp. Dev. Off | ▼ SALG | -45.887 | -41.147 USD | sec |
| 18.5.2026 | Parikh Shamik J | Chief Medical Officer | ▼ SALG | -45.887 | -41.147 USD | sec |
Earnings
| Quarter | Date | EPS actual | EPS est | EPS surprise | Revenue surprise | |
|---|---|---|---|---|---|---|
| 2026Q1 | 30.4.2026 | -0,09 | -0,12 | +21.7% | +21.7% | Beat |
| 2025Q4 | 30.1.2026 | -0,13 | -0,14 | +3.7% | +3.7% | Inline |
| 2025Q3 | 30.10.2025 | -0,11 | -0,15 | +25.8% | +25.8% | Beat |
| 2025Q2 | 30.7.2025 | -0,24 | -0,18 | -35.9% | -35.9% | Miss |